Atıf İçin Kopyala
Durmaz Y., İlhanlı İ.
EGYPTIAN RHEUMATOLOGIST, cilt.43, sa.3, ss.253-256, 2021 (ESCI)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
43
Sayı:
3
-
Basım Tarihi:
2021
-
Doi Numarası:
10.1016/j.ejr.2021.05.001
-
Dergi Adı:
EGYPTIAN RHEUMATOLOGIST
-
Derginin Tarandığı İndeksler:
Emerging Sources Citation Index (ESCI), Scopus, EMBASE, Directory of Open Access Journals
-
Sayfa Sayıları:
ss.253-256
-
Anahtar Kelimeler:
Covid-19, Immunoglobulin levels, Rheumatoid arthritis, Rituximab, IMMUNOGLOBULIN LEVELS, EFFICACY, SAFETY, RISK, MAINTENANCE, RETREATMENT, INFECTIONS, THERAPY, TRIAL
-
Ondokuz Mayıs Üniversitesi Adresli:
Evet
Özet
Aim of the work: To evaluate the 6-month treatment responses to low dose rituximab (LDR) compared to standard dose rituximab (SDR) in rheumatoid arthritis (RA) patients whose treatments were disrupted due to the pandemic with increased disease activity and to examine the effect of LDR treatment on serum immunoglobulin (Ig) levels.